Akari医疗公共 AKTX 深 沪
等待开盘 07-22 09:30:00 美东时间
1.135
+0.005
+0.44%
华盛通- 最 高1.14
- 今 开1.14
- 成交量 7.05万股
- 最 低 1.1002
- 昨 收 1.13
- 总市值 3652.02万
- 52周最高 4.2185
- 市盈率 静 --
- 换手率 0.22%
- 52周最低 0.85
- 委 比 -99.49%
- 总股本 3217.64万
- 历史最高 2380.00
- 量 比 3.57
- 振 幅 3.52%
- 历史最低 0.85
- 每 手 1
- 风险率 0.98%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅163.16%！Craig-Hallum上调DiaMedica Therapeutics目标价至11美元，维持"买入"评级
今日重点评级关注：Craig-Hallum：维持DiaMedica Therapeutics"买入"评级，目标价从8美元升至11美元；花旗：维持Cogent Biosciences"买入"评级，目标价从15美元升至22美元
07-21 09:19
Maxim Group Initiates Coverage On Akari Therapeutics with Buy Rating, Announces Price Target of $5
Maxim Group analyst Jason McCarthy initiates coverage on Akari Therapeutics (NASDAQ:AKTX) with a Buy rating and announces Price Target of $5.
07-19 00:28
Akari Therapeutics Shareholders Approve Key AGM Resolutions
Akari Therapeutics ( ($AKTX) ) has issued an update. On June 30, 2025, Akari Th...
07-02 05:55
Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent
Akari Therapeutics, a biotech company focused on developing novel immuno-oncology ADCs, recently participated in a Virtual Investor segment discussing their India Patent No. 562,919 for "Thailanstatin Analogs." The patent covers their PH1 payload, linkers, and ADC technology applicable to various cancer targets. Akari's PH1 payload, a spliceosome inhibitor, disrupts RNA splicing in cancer cells, inducing cell death and activating immune response....
06-25 13:00
Akari Therapeutics Secures Indian Patent For PH1 Spliceosome Inhibitor Payload And ADC Technology Targeting Cancer
Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activation of immune system through multiple mechanismsIndia represents a key territory with a
06-18 20:53
Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India
Akari Therapeutics获得印度专利局授予的第562919号专利，覆盖其PH1载药、非可裂解和可裂解连接剂及其ADC技术，用于多种癌症治疗。PH1是一种剪接体抑制剂，通过干扰RNA剪接诱导癌细胞死亡并激活免疫系统。鉴于印度癌症发病率持续增长， компани 예상，该专利将增强公司在印度市场的知识产权布局，促进创新癌症疗法的开发。 Akari的PH1载药在美国和中国等多个国家已获得专利保护，目前公司正在推进一系列潜在同类首创新药ADC候选药物的研发，这些药物在临床前研究中展现了显著的抗肿瘤活性和免疫激活效果。
06-18 12:50
Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology
Akari Therapeutics是一家专注于开发下一代有效载荷抗体药物偶联物（ADC）的肿瘤学生物技术公司，其主要候选药物AKTX-101通过靶向Trop2受体，利用新型PH1有效载荷直接作用于肿瘤，通过抑制RNA剪接诱导癌细胞死亡并激活免疫系统。公司近日发布了“Meet the Team”视频，介绍新任高管Mark F. Kubik，同时在其官网上提供了更多相关信息。
05-29 13:15
Akari Therapeutics Q1 2025 $(0.00), Inline YoY
Akari Therapeutics (NASDAQ:AKTX) will report on Q1 2025.
05-15 20:23
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) stock moved upwards by 63.1% to $...
04-23 05:05
Akari Therapeutics GAAP EPS of $0.00
Akari Therapeutics press release (NASDAQ:AKTX): FY GAAP EPS of $0.00. As of December 31, 2024, the Company had cash of approximately $2.6 million. More on Akari Therapeutics Akari Therapeutics annou...
04-17 01:51
